The iQue^® Advanced Flow Cytometer allows researchers to acquire and analyze high content, multiplexed assays needed to assess immune cell function by combining cell immuno-phenotyping, cell health, and secreted protein (cytokine) analysis in every well of a microtiter plate. Accelerate your research by resolving complex cellular research questions via multiplexed analysis in a single well.

Generate relevant and accurate data through simultaneous analysis of multiple biological readouts and quickly identify your next discovery.

• Get biologically relevant insights - Perform comprehensive, multiplexed analysis of cells, beads and secreted proteins all from the same cells at the same timepoint for coherent biological data.
• Maximize your productivity - Relieve capacity bottlenecks with optimized, multiplexed assays paired with the fastest plate sampling and integrated analysis – reduce data analysis times from days to minutes.
• Conserve precious samples - Sample as little as a single microliter from miniaturized assay volumes - ideal for rare, expensive cell populations.

Detection of Anti-SARS-CoV-2 IgG, IgM and IgA Using Advanced Flow Cytometry
Advance your COVID-19 research by obtaining a comprehensive profile of antibodies against SARS-CoV-2 using a multiplex and high throughput serological assay.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to persist due to constant mutation and evasion. Because development of a humoral immune response against this virus is critical for protection, there is an ongoing need to accurately assess the quantity and duration of antibody responses against SARS-CoV-2, particularly antibodies targeting the SARS-CoV-2 Spike protein receptor binding domain (RBD). The SARS-CoV-2 Spike RBD mediates viral entry into human cells by binding to the angiotensin-converting enzyme 2 (ACE2) and is the primary target of many COVID-19 vaccines currently in use. Antibodies against the SARS-CoV-2 Spike RBD generally have potent viral neutralizing activity and correlate with protective immunity against the virus. Serological testing to quantitate the three major isotypes (IgG, IgM and IgA) of antibodies specific for SARS-CoV-2 Spike RBD can be used to facilitate characterization and monitor the duration of antibody responses in both COVID-19 patients and vaccinated individuals, detect asymptomatic infections and survey past infection prevalence in a population.

There are several methods for detecting anti-SARS-CoV-2 Spike RBD IgG, IgM or IgA antibodies, including a traditional enzyme-linked immunosorbent assay (ELISA), lateral flow immunoassay and flow cytometry. However, these methods have limitations:

• Provide only qualitative results
• Low sensitivity and specificity
• Can be labor-intensive and may not support high-throughput applications
• Do not allow multiplexing analysis of IgG, IgM and IgA antibodies
• Require large amounts of reagents

The iQue^® SARS-CoV-2 (IgG, IgM and IgA) kit provides a rapid, robust and sensitive serological assay for the measurement of IgG, IgM and IgA anti-SARS-CoV-2 Spike RBD antibodies in a single well of a 96 or 384-well plate with antibody detection levels in the pg/mL range. Combined detection of all three antibody isotypes  saves time and precious patient samples and provides a dynamic, comprehensive profile of humoral immune responses over time following natural infection with SARS-CoV-2 or immunization with COVID-19 vaccines. Accelerate research with the iQue^® SARS-CoV-2 (IgG, IgM and IgA) kit!

Visit Sartorius AG here or use the Request Information button below to contact the supplier.